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Background:  Rocuronium-induced withdrawal movements can be harmful to patients during the induction period.   
Remifentanil has been reported to reduce these movements effectively.  In this study, we determined the EC50 of 
remifentanil for the prevention of rocuronium induced withdrawal movements in male, female, old and child group.
Methods:  We included patients scheduled for general anesthesia and assigned them into 4 groups depending on 
their age and gender:  male group (20-60 yr), female group (20-60 yr), old group (>65 yr) and child group (6-
12 yr). Remifentanil was administered by target controlled infusion.  Propofol 2 mg/kg was then administered after 
equilibration between the effect and plasma concentration of remifentanil was reached.  After loss of consciousness, 
rocuronium 0.6 mg/kg was administered.  Patient’s response to the rocuronium was graded using a 4 point scale 
in a blinded manner.  The EC50 of remifentanil for preventing rocuronium induced withdrawal movements was 
determined using Dixon’s up-and -down method.
Results:  The EC50 of remifentanil for preventing rocuronium induced withdrawal movements was 1.8 ± 0.5 ng/ml [95% 
confidence interval 1.3-2.2] in the male group, 2.3 ± 1.0 ng/ml [1.3-3.2] in the female group, 0.5 ± 0.4 ng/ml [0.2-0.8] 
in the old group and 2.8 ± 0.8 ng/ml [2.1-3.5] in the child group.
Conclusions:  The EC50 of remifentanil for preventing rocuronium induced withdrawal movements was lowest in the 
elderly and higher in children than male adult patients.  No difference in the EC50 of remifentanil was seen between 
male and female adult patients.   (Korean J Anesthesiol 2010; 58: 244-248)
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Introduction
    Pain from rocuronium injection has been reported to occur 
in 50-100% of patients [1-3]. The pain has been described as 
intense and burning sensation in conscious patients [2,4]. This 
injection pain can elicit reflex withdrawal movements of the 
injected hand and arm or generalized movements of the body 
in unconscious patients [5]. These withdrawal movements may 
dislodge or displace intravenous catheter and can be harmful to 
children during the induction period.
    Remifentanil is a synthetic and esterase metabolized opioid. 
It has a rapid onset and an ultra-short duration of action with 
a stable, short context-sensitive half time [6]. It was reported to 
effectively reduce rocuronium injection pain and withdrawal 
movements [7]. 
    The incidence and severity of rocuronium induced pain differ 
with age and gender. It is estimated to be higher in female [8,9] 
and pediatric patients [10].
    The aim of the present study was to determine and compare 
the EC50 of remifentatnil to prevent withdrawal movements in 
male, female, child and old patients.
Materials and Methods
    After obtaining approval from the institutional review board 
and written informed consent from the patients or parents, we 
enrolled 102 ASA physical status I or II patients undergoing 
general anesthesia. Patients with a history of neurological 
deficits, allergies to opioids and local anesthetics, or asthma, 
and those who had received analgesics or sedatives within the 
previous 24 hr were excluded from the study.
    Patients were allocated into 4 groups according to their age 
and gender: male group (20-60 yr, n = 23), female group (20-60 
yr, n = 24), old group (>65 yr, n = 26). child group (6-12 yr, n = 
29). All patients were not premedicated. A 20 gauge intravenous 
(IV) cannula for adults or a 22 gauge IV cannula for children 
was inserted into the dorsum of the hand without subcutaneous 
lidocaine infiltration at about 2 h before the induction of 
anesthesia on the ward. Ringer’s lactate solution was chosen for 
IV fluid for adults and dextrose-saline solution for children. On 
arrival in the operating room, each patient’s electrocardiogram, 
pulse oximetry and non-invasive blood pressure were 
monitored and a mask delivering 5 L/min of O2 was loosely 
applied on the patients. Atropine 0.01 mg/kg was administrated 
for preventing bradycardia in the child group. Remifentanil 
was administrated by target controlled infusion via a syringe 
pump (Pilot Anesthesia 2, Fresenius vial, France) driven by 
STELPUMP (Ver.1.07). Minto et al.’s pharmacokinetic model was 
used [11]. Preliminary studies suggested an initial target effect 
site remifentanil concentration of 4.0 ng/ml. After equilibration 
of plasma and effect site remifentanil concentration, 
propofol 2 mg/kg was administered. Immediately after loss 
of consciousness and eyelash reflex, mask ventilation was 
started with 5 L/min of O2 and 1% rocuronium at 0.6 mg/kg 
was administered over 5 s into a port connected directly to the 
IV cannula. The withdrawal movements were observed by the 
same blinded investigator using the 4-grading system which 
has been utilized in several previous studies (Table 1) [12]. A 
grade of 2 or more was regarded as significant movements. After 
estimating the withdrawal movements, anesthesia was induced 
with sevofluane 3-5 vol% and O2 100% and tracheal intubation 
was performed 120 s later. Anesthesia was maintained with 
sevoflurane 1-5 vol% and 50% nitrous oxide in oxygen.
    The EC50 of remifentanil for preventing rocuronium induced 
withdrawal movements was determined by a modification of 
Dixon’s up-and-down method [13]. If the patient’s response 
was grade 2 or 3, the target concentration of remifentanil in the 
next patient was increased by a step of 0.5 ng/ml. If the patient’s 
response was grade 0 or 1, a decrease of 0.5 ng/ml was made. 
The process was repeated until the seventh cross-over point 
(grade 2,3/0,1) was obtained. The midpoint was defined as the 
mean cross-over concentration. The EC50 was defined as the 
mean cross-over mid point in each group. 
    Side effects such as bradycardia, hypotension, O2 desaturation 
and difficulty in mask ventilation due to chest rigidity were 
recorded. Bradycardia and hypotension were defined as a 
decrease of >20% from their respective preoperative value. O2 
desaturation was defined as SpO2 decreasing to <90%.
    Statistical analyses were performed using SPSS 11.0. Probit 
analysis was used for calculating the confidence interval and 
plotting the dose response curve. Values are expressed as mean 
± SD or number of patients. P value of <0.05 was considered to 
be statistically significant.
Table 1. Grading of Withdrawal Movements
Degree of 
movements
Patient’s response
0
1
2
3
No response or withdrawal
Movementsat the wrist only
Movements/withdrawal involving arm only
Generalized response-withdrawal or movements in 
  more than one extremity, cough, or breath holding
Table 2. Characteristics of Patients
  Group-M     Group-F   Group-O Group-C
Gender (M/F)
Age (years)
Height (cm)
Weight (kg)
  23/0
   37.9 ± 12.5
172.4 ± 6.7
   75.3 ± 11.9
     0/24
    42.8 ± 10.9
156. 8 ± 6.6
    60.2 ± 15.0
   10/16
  70.7 ± 5.0
156.2 ± 7.9
  59.9 ± 9.8
  16/13
  8.6 ± 2.5
134.5 ± 19.0
  32.6 ± 13.2
Values are mean ± SD or number. M: male, F: female, O: old, C: child.246 www.ekja.org
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Results
    Table 2 presents the patients’ demographic data. Table 3 
presents the hemodynamic data during the induction period. 
There were no cases of significant hypotension, bradycardia 
or O2 desaturation. The incidence of significant withdrawal 
movements was 39% (9/23) for the male group, 38% (9/24) for 
the female group, 31% (8/26) for the old group and 45% (13/29) 
for the child group in all the study remifentanil concentration. 
Table 4 presents the grade of withdrawal movements in each 
group. 
    EC50 of remifentanil for preventing rocuronium induced 
withdrawal movements was 1.8 ± 0.5 ng/ml [95% confidence 
interval, 1.3-2.2] in the male group, 2.3 ± 1.0 ng/ml [1.3-3.2] in 
Table 3. Mean Blood Pressure and Heart Rate during Study Period
Baseline Post-Remi Post-Rocu
MBP (mmHg)
HR (beats/min)
Group-M
Group-F
Group-O
Group-C
Group-M
Group-F
Group-O
Group-C
96.4 ± 9.2
96.7 ± 12.9
104.3 ± 12.9
83.5 ± 10.4
74.5 ± 16.1
75.3 ± 16.7
70.0 ± 12.1
95.2 ± 15.3
94.7 ± 9.6
92.2 ± 10.8
102.2 ± 13.4
72.8 ± 10.9
73.9 ± 17.7
74.2 ± 14.4
67.8 ± 9.2
85.5 ± 16.1
79.1 ± 19.8
77.7 ± 12.3
84.1 ± 13.6
67.7 ± 7.8
71.5 ± 12.4
67.3 ± 12.5
64.7 ± 11.8
91.2 ± 15.5
Values are mean ± SD. MBP: mean blood pressure, HR; heart rate, 
Post-Remi: immediately after reaching the equilibrium between 
effect and plasma concentrationof remifentanil, Post-Rocu: 
immediately after the injection of rocuronium.
Table 4. Incidence and Grade of Withdrawal Movements induced by 
Rocuroniun Injection
Grade Group-M Group-F Group-O Group-C
0
1
2
3
11 (48)
  3 (13)
2 (9)
  7 (30)
12 (50)
  3 (13)
  3 (13)
  6 (25)
15 (58)
  3 (12)
  6 (23)
2 (8)
16 (55)
0 (0)
  6 (21)
  7 (24)
Values are number (%). M: male, F: female, O: old, C: child.
Fig. 1. Consecutive target remifentanil concentrations for determining the EC50. The arrow represents the mean remifentanil concentration 
when crossing from significant movements (grade 2,3) to no movements (grade 0,1). The average of these concentrations is the EC50. EC50 is 1.8 
± 0.5 ng/ml in male adult, 2.3 ± 1.0 ng/ml in female adult, 0.5 ± 0.4 ng/ml in old and 2.8 ± 0.8 ng/ml in child group.247 www.ekja.org
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the female group, 0.5 ± 0.4 ng/ml [0.2-0.8] in the old group and 
2.8 ± 0.8 ng/ml [2.1-3.5] in the child group.
    The old group required significantly lower effect site 
concentration of remifentanil for preventing rocuronium 
withdrawal movements than the other groups (vs. child 
group P = 0.00, vs. male group P = 0.01, vs. female group P 
= 0.00). The child group required significantly higher effect 
site concentration than the male group (P = 0.04). There was 
no significant difference in the effect site concentration of 
remifentanil between the male group and female group (P = 
0.56) (Fig. 1,  2).
Discussion
    The mechanism of rocuronium induced pain remains unclear. 
It has been suggested that aminosteroidal neuromuscular 
blocking drugs such as rocuronium and vecuronium, induce 
pain by directly activating the C-nociceptor [14]. Because 
rocuronium is less potent neuromuscular blocking drug than 
vecuronium, a higher dose or concentration is required to 
induce muscle relaxation. This higher dose or concentration has 
been suggested as the reason for more frequent and severe pain 
with rocuronium injection [14].
    Pretreatment with opioid has been known to effectively 
prevent rocuronium induced withdrawal movements [6,11,13]. 
The central and peripheral sites of action of opioids participate 
in reducing injection pain but the main site of action is central 
[15,16]. Therefore, the 90 s time interval between the injection 
of remifentanil and rocuronium was recommended to allow for 
the opioid’s maximal effect.
    Previous studies suggested that the withdrawal movements in 
children are more intense than in adults [10]. Our study showed 
that children required a higher remifentanil concentration for 
preventing withdrawal movements than in the male adult group 
and old group. Because the rocuronium induced withdrawal 
movements can be of harm to children during the induction 
period, appropriate pretreatment is required. An opioid, 
especially remifentanil, is more appropriate than other drugs in 
preventing withdrawal movements in pediatric patients [7]. The 
absence of side effects such as bradycardia, hypotension and O2 
desaturation, as was noted in this study, makes remifentanil a 
better choice in preventing withdrawal movements.
    The old group required a lower remifentanil concentration 
than the other groups in our study. This can be explained in 
part by the pharmacokinetic and pharmacodynamic changes 
of remifentanil among the elderly. Age is inversely related to 
the central volume of distribution, clearance, and potency of 
remifentanil [17].
    Female patients complained of more severe pain than male 
[9,18]. Kim et al. [10] reported that females show rocuronium 
induced withdrawal movements 2.1 times more frequently 
than males in the adult group but there is no gender influence 
in children. It has been suggested that the gender difference in 
severity and incidence of rocuronium induced pain in adults 
may be related with sex hormones. We however, did not find 
any difference in the remifentanil EC50 between male and 
female adult groups. The opioid is known to be more potent in 
female than male [19]. But Minto et al reported that the potency 
of remifentanil was not influenced by gender [11].
    In conclusion, we found that the EC50 of remifentanil for 
preventing rocuronium induced withdrawal movements is 
lowest in the elderly in the all groups and higher in children 
when compared to adult male patients. No such difference was 
seen between male and female adult patients.
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